Sun Pharma: Traction in speciality likely to sustain
Sun Pharma's key specialty products, particularly Ilumya (plaque psoriasis) and Cequa (dry eye disease), held up well
May 31, 2021 / 10:53 AM IST
Revlimid is a blockbuster blood cancer drug with sales of $12.1 billion for BMS in 2020.
PRO Only Highlights
Quarterly performance largely backed by improved realisations
Medium-term triggers China plus and protectionist measures for tyre industry
Valuations not inexpensive; but improved medium-term outlook
India’s largest pharma company, Sun Pharma (CMP: Rs 670, Market Cap: Rs 160,695 crore), posted a decent growth in domestic formulations in the quarter gone by. However, the improving outlook for global specialty business calls for attention.
Sales of specialty products clocked $139 million (versus $148 million in Q3 FY21), sequentially weaker due to some pre-buying at the end of the last calendar year. However, compared to last year, sales were up 10 per cent. Key specialty products, particularly Ilumya...